Abstract
Objective: Using a comprehensive systematic review and meta-analysis, we studied the global epidemiology of migraine at the community level to determine its true prevalence and burden. Background: Migraine is one of the most common chronic conditions worldwide, and contributes significantly to the burden of disease. Methods: A systematic review using advanced search strategies employing PubMed/MEDLINE, Scopus, and Web of Science inclusive of relevant gray literature handsearch was conducted for community-based studies by combining the terms ‘‘migraine’’, ‘‘community-based’’, and names of every country worldwide spanning all previous years until August 31, 2015. Methods were in accordance with PRISMA and MOOSE guidelines. A meta-analysis with sensitivity analysis was performed to identify pooled migraine prevalence and examine cohort heterogeneity. Results: A total of 302 community-based studies involving 6,216,995 participants (median age 35 years, male to female ratio of 0.91) were included. 87 [percnt] of the studies were from post-ICHD era (International Classification of Headache Disorders 1988); 82[percnt] of these applied ICHD diagnostic criteria. 30 [percnt] of the studies were school-based. Pooled crude migraine prevalence was 11.6[percnt] (95[percnt] Confidence Interval [CI] 10.7-12.6[percnt]; random effects); 10.4[percnt] in Africa, 10.1[percnt] in Asia, 11.4[percnt] in Europe, 9.7[percnt] in North America, 16.4[percnt] in Central and South America. Pooled cohort-stratified migraine prevalence was 13.8[percnt] among females, 6.9[percnt] among males, 11.2[percnt] among urban residents, 8.4[percnt] among rural residents, and 12.4[percnt] among school/college students. Sensitivity analysis revealed similar random-effects weighted prevalence between ICHD-using studies (11.2[percnt]) and all studies (11.6[percnt]), likewise between one-year (11.9[percnt]) and all studies (11.6[percnt]). Conclusions: Migraine affects one in ten people worldwide; it is twice common in females. Higher prevalence was found among school/college students and urban residents. Geographical variations were observed with Central and South American region featuring higher prevalence compared to other regions with comparable prevalence.
Disclosure: Dr. Woldeamanuel has nothing to disclose. Dr. Cowan has received personal compensation for activities with Allergan, Inc., MAP Pharmaceuticals, Nautilus Neurosciences, and Nupathe.
Thursday, April 21 2016, 8:30 am-5:30 pm
- Copyright © 2016 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.